SCHEMBL25072518

SCHEMBL25072518

O=C(O)c1cc(NS(=O)(=O)c2cnc(-c3ccc(F)cc3)s2)co1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTPN11 Q06124 1/20 0.40
▸ MAPT P10636 3/20 0.36
▸ RAB9A P51151 3/20 0.36
▸ MEN1 O00255 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ KDM4E B2RXH2 2/20 0.36
▸ GLA P06280 2/20 0.36
▸ NPC1 O15118 2/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ HSP90AA1 P07900 1/20 0.36
▸ GAA P10253 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ RORC P51449 1/20 0.36
▸ NPSR1 Q6W5P4 2/20 0.35
▸ POLB P06746 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ CSNK2A2 P19784 1/20 0.34
▸ CSNK2A1 P68400 1/20 0.34
▸ ATM Q13315 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25073028 0.83 PTPN11 (0.44) PTPN11MAPTRAB9AMEN1KMT2A
SCHEMBL25072408 0.82 PTPN11 (0.51) PTPN11MAPTRAB9AMEN1KMT2A
SCHEMBL25073360 0.81 FABP4 (0.45) PTPN11MAPTRAB9AMEN1KMT2A
SCHEMBL25073308 0.81 P4HTM (0.49) PTPN11MAPTRAB9AMEN1KMT2A
SCHEMBL25073201 0.80 PTPN11 (0.42) PTPN11MAPTRAB9AMEN1KMT2A
SCHEMBL25073318 0.80 PFKFB3 (0.53) PTPN11MEN1KMT2APOLBPFKFB3
SCHEMBL25073082 0.80 PTPN11 (0.39) PTPN11MAPTRAB9AMEN1KMT2A
SCHEMBL25073315 0.80 KMT2A (0.49) PTPN11MAPTRAB9AMEN1KMT2A
SCHEMBL25073045 0.80 PFKFB3 (0.50) PTPN11MAPTMEN1KMT2AKDM4E
SCHEMBL30278475 0.79 PTPN11 (0.46) PTPN11MAPTRAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230143250-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2023-05-11 — — US disclosed
US-20230143250-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2023-05-11 — — US disclosed
WO-2023023310-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. (US) 2023-02-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230143250-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF HSD17B1, HSD17B13, HSD17B3 PTPN11 3612/4885MAPT 3642/4885RAB9A 3762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback